A Study of APG-3288 in Relapsed/Refractory Blood Cancers | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of APG-3288 in Relapsed/Refractory Blood Cancers	B-cell neoplasm, Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Waldenstrom macroglobulinemia, cardiovascular disorder, diffuse large B-cell lymphoma, follicular lymphoma, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2026-07-30		NCT07424833

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ascentage Pharma Group Inc.	30

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Henan Cancer Hospital	Zhengzhou	China	98
Mayo Clinic	Jacksonville	United States	122
START Los Angele	Los Angeles	United States	1
START Midwest	Grand Rapids	United States	79
START New Jersey	East Brunswick	United States	16
The University of TX MD Anderson Cancer Center	Houston	United States	1